Adaptive immune effector cells (None)

Adaptive immune effector cells, primarily comprising T lymphocytes and B lymphocytes, are the specialized components of the immune system that provide antigen-specific defense and establish immunological memory (StatPearls, 2023). T cells, including cytotoxic (CD8+) and helper (CD4+) subsets, recognize specific antigens to directly kill infected or cancerous cells and orchestrate the broader immune response (NIH, 2022). B cells differentiate into plasma cells that produce antibodies to neutralize pathogens and facilitate their clearance (Wikipedia, 2024). These cells are central to modern immunotherapy; for instance, checkpoint inhibitors release the 'brakes' on T cells to fight cancer, while CAR-T cell therapies involve engineering T cells to target specific tumor markers (Nature Reviews Cancer, 2021). However, dysregulation of these cells can lead to autoimmune diseases, where the immune system attacks the body's own tissues, or graft-versus-host disease following transplantation (PubMed, 2020).

Other names

T lymphocytesB lymphocytesEffector T cellsPlasma cellsCytotoxic T lymphocytesHelper T cellsAdaptive lymphocytes

Drugs targeting adaptive immune effector cells primarily act through immune checkpoint inhibition to enhance T-cell activity, chimeric antigen receptor (CAR) engineering to redirect cell specificity toward tumor antigens, monoclonal antibody-mediated depletion of specific cell subsets, or pharmacological suppression of activation pathways to treat autoimmunity and prevent transplant rejection (Nature Reviews Drug Discovery, 2022; StatPearls, 2023).